These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11806486)

  • 1. Effects of atypical antipsychotics on weight and serum lipid levels.
    Meyer JM
    J Clin Psychiatry; 2001; 62 Suppl 27():27-34; discussion 40-1. PubMed ID: 11806486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hyperlipidemia--side-effect of the treatment with an atypical antipsychotic (zotepine)?].
    Wetterling T
    Psychiatr Prax; 2002 Nov; 29(8):438-40. PubMed ID: 12436365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics.
    Meltzer HY
    J Clin Psychiatry; 2001; 62 Suppl 27():35-9; discussion 40-1. PubMed ID: 11806488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapidly worsening hypertriglyceridemia during treatment with risperidone.
    Kohen I; Manu P
    Am J Ther; 2010; 17(2):216-8. PubMed ID: 19455018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
    Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
    Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity.
    Van Gaal LF
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S142-8. PubMed ID: 16863690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schizophrenia and obesity: impact of antipsychotic medications.
    Wirshing DA
    J Clin Psychiatry; 2004; 65 Suppl 18():13-26. PubMed ID: 15600381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical antipsychotic therapy and hyperlipidemia: a review.
    Koro CE; Meyer JM
    Essent Psychopharmacol; 2005; 6(3):148-57. PubMed ID: 15869022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
    Newcomer JW
    J Clin Psychiatry; 2004; 65 Suppl 18():36-46. PubMed ID: 15600383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical implications of weight gain in schizophrenia.
    Kurzthaler I; Fleischhacker WW
    J Clin Psychiatry; 2001; 62 Suppl 7():32-7. PubMed ID: 11346194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dyslipidemia and schizophrenia].
    Wetterling T; Schneider B; Weber B
    Psychiatr Prax; 2007 Jul; 34(5):223-9. PubMed ID: 17160750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone-associated increase in triglyceride levels.
    Weinbrenner A; Peus V; Inta D; Englisch S; Zink M
    Am J Psychiatry; 2009 Jan; 166(1):113-4. PubMed ID: 19122019
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.
    Chen CK; Chen YC; Huang YS
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):17-22. PubMed ID: 19067997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic risk during antipsychotic treatment.
    Newcomer JW
    Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hyperlipidemia - side-effect of "Atypical" neuroleptics?].
    Wetterling T
    Fortschr Neurol Psychiatr; 2003 Oct; 71(10):535-40. PubMed ID: 14551854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Schizophrenia, obesity and pharmacotherapy-associated weight gain].
    Carpiniello B; Corda E; Maccioni R; Pinna F
    Clin Ter; 2008; 159(5):299-306. PubMed ID: 18998030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic induced weight gain in schizophrenia:mechanisms and management.
    Rege S
    Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.